Physician profile
Samuel Robert Althauser
NPI 1306224050
$4,414.39
in general payments reported to CMS, 2019-2025
22 companies · $942 in 2025
The $942 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $727 · 2021: $1,544 · 2022: $215 · 2023: $228 · 2024: $413 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,239.68 | 2021-2025 | Vraylar, Ubrelvy |
| Neurocrine Biosciences, INC. | $506.14 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $506.03 | 2019-2025 | Trintellix |
| Allergan, INC. | $366.13 | 2019-2020 | |
| Lundbeck LLC | $231.18 | 2020-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $186.11 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $184.21 | 2020-2025 | Caplyta |
| Bausch Health US, LLC | $178.89 | 2021-2025 | Aplenzin, Wellbutrin |
| Alkermes, INC. | $136.04 | 2021-2025 | Aristada, Lybalvi |
| Brainsway USA INC | $135.97 | 2025 | Deep Tms |
| Otsuka America Pharmaceutical, INC. | $116.10 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $111.77 | 2021-2025 | Austedo Xr |
| Merck Sharp & Dohme LLC | $85.81 | 2020-2021 | |
| Axsome Therapeutics, INC. | $77.40 | 2025 | Sunosi, Auvelity |
| Janssen Pharmaceuticals, INC | $68.64 | 2020-2025 | Spravato |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $60.21 | 2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $52.52 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $46.10 | 2024-2025 | Nuplazid |
| Avanir Pharmaceuticals, INC. | $42.50 | 2019 | |
| Vanda Pharmaceuticals INC. | $40.24 | 2025 | Fanapt |
| Almatica Pharma LLC | $21.62 | 2025 | Loreev Xr |
| Sun Pharmaceutical Industries INC. | $21.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Althauser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.